-
公开(公告)号：US09290558B2
公开(公告)日：2016-03-22
申请号：US13692324
申请日：2012-12-03
Applicant: Wake Forest University Health Sciences
Inventor： Waldemar Debinski , Jill Wykosky , Denise Mazess Herpai
IPC: C07K14/00 , A61K51/08 , A61K38/00 , C07K14/705 , A61K47/48 , A61K49/00 , C07K14/52 , A61K38/17 , A61K38/20 , A61K45/06
CPC classification number: A61K38/177 , A61K38/00 , A61K38/2086 , A61K38/45 , A61K45/06 , A61K47/64 , A61K47/642 , A61K47/6801 , A61K49/0002 , C07K14/52 , C07K14/705 , C12Y204/02036
Abstract: The present invention provides compounds, compositions, and methods for detecting, diagnosing and treating cancers such as glioblastoma multiforme.
-
公开(公告)号：US20140255471A1
公开(公告)日：2014-09-11
申请号：US14202304
申请日：2014-03-10
Applicant: Wake Forest University Health Sciences
Inventor： William H. Gmeiner , Waldemar Debinski
IPC: A61K31/7115 , A61N5/10 , A61K31/4535 , A61K9/00 , A61K31/4188
CPC classification number: A61K31/7115 , A61K9/0085 , A61K9/127 , A61K9/19 , A61K31/4188 , A61K31/4535 , A61K31/7088 , A61K45/06 , A61N5/10 , A61K2300/00
Abstract: Provided herein are methods useful for treating a brain tumor in a subject in need thereof, comprising administering to said subject an active agent comprising poly-FdUMP or a pharmaceutically acceptable salt thereof. Also provided are compositions comprising poly-FdUMP and one or more additional active agents useful for treating a brain tumor.
Abstract translation: 本文提供了可用于治疗有需要的受试者的脑肿瘤的方法，包括向所述受试者施用包含聚FdUMP的活性剂或其药学上可接受的盐。 还提供了包含聚-FdUMP和一种或多种用于治疗脑肿瘤的另外的活性剂的组合物。
-
公开(公告)号：US20220062376A1
公开(公告)日：2022-03-03
申请号：US17527835
申请日：2021-11-16
Applicant: Wake Forest University Health Sciences
Inventor： Waldemar Debinski , Jill Wykosky , Denise Mazess Herpai
IPC: A61K38/17 , A61K49/00 , C07K14/52 , A61K47/64 , A61K47/68 , A61K38/20 , A61K45/06 , C07K14/705 , A61K38/45
Abstract: The present invention provides compounds, compositions, and methods for detecting, diagnosing and treating cancers such as glioblastoma multiforme.
-
公开(公告)号：US11207380B2
公开(公告)日：2021-12-28
申请号：US15957445
申请日：2018-04-19
Applicant: Wake Forest University Health Sciences
Inventor： Waldemar Debinski , Jill Wykosky , Denise Mazess Herpai
IPC: A61K47/64 , A61P35/00 , A61K38/17 , A61K49/00 , C07K14/52 , A61K47/68 , A61K38/20 , A61K45/06 , C07K14/705 , A61K38/45 , A61K38/00
Abstract: The present invention provides compounds, compositions, and methods for detecting, diagnosing and treating cancers such as glioblastoma multiforme.
-
公开(公告)号：US20210395324A1
公开(公告)日：2021-12-23
申请号：US17465145
申请日：2021-09-02
Applicant: Wake Forest University Health Sciences
Inventor： Waldemar Debinski , Hetal Pandya , Denise Gibo
IPC: C07K14/54 , A61K47/64 , C07K14/34 , G01N33/50 , G01N33/532 , G01N33/68 , C07K14/21 , C07K19/00 , C07K14/005 , C07K14/195
Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.
-
Patent Agency Ranking
公开(公告)号：US20200347113A1
公开(公告)日：2020-11-05
申请号：US16947154
申请日：2020-07-21
Applicant: Wake Forest University Health Sciences
Inventor： Waldemar Debinski , Carla Lema Tome , Sara Ferluga , Poonam S. Sonawane
IPC: C07K14/705 , C07K14/52 , C07K14/54 , G01N33/574
Abstract: Provided herein is a construct comprising, in combination: an EphA3, EphA2 and/or EphB2 binding ligand; and at least one effector molecule. In some embodiments, the at least one effector molecule comprises a therapeutic agent, a nanoparticle, a detectable group, a lipid, or a liposome. In some embodiments, the construct is a fusion protein and/or a covalent conjugate. Further provided is a construct comprising, in combination: a ligand that binds to EphA2, EphA3 and/or EphB2; a ligand that binds to IL-13Rα2; and at least one effector molecule. Also provided are methods of use thereof for treating cancer.
-
公开(公告)号：US09878013B2
公开(公告)日：2018-01-30
申请号：US15045557
申请日：2016-02-17
Applicant: Wake Forest University Health Sciences
Inventor： Waldemar Debinski , Hetal Pandya , Denise Mazess Herpai
CPC classification number: A61K38/2086 , A61K38/00 , A61K38/08 , A61K38/10 , A61K47/64 , A61K47/6415 , C07K7/06 , C07K7/08 , C07K14/5437 , C07K2319/01 , C07K2319/55
Abstract: A targeting peptide that specifically binds to an IL13 receptor (e.g., wherein said targeting peptide is not an IL13 fragment) is described. The targeting peptide is optionally conjugated to at least one effector molecule. In some embodiments, the peptide specifically binds to the IL13Rα2 protein.
-
公开(公告)号：US20160193289A1
公开(公告)日：2016-07-07
申请号：US15018991
申请日：2016-02-09
Applicant: Wake Forest University Health Sciences
Inventor： Waldemar Debinski , Jill Wykosky , Denise Mazess Herpai
CPC classification number: A61K38/177 , A61K38/00 , A61K38/2086 , A61K38/45 , A61K45/06 , A61K47/64 , A61K47/642 , A61K47/6801 , A61K49/0002 , C07K14/52 , C07K14/705 , C12Y204/02036
Abstract: The present invention provides compounds, compositions, and methods for detecting, diagnosing and treating cancers such as glioblastoma multiforme.
-
公开(公告)号：US20160175399A1
公开(公告)日：2016-06-23
申请号：US15045557
申请日：2016-02-17
Applicant: Wake Forest University Health Sciences
Inventor： Waldemar Debinski , Hetal Pandya , Denise Mazess Herpai
CPC classification number: A61K38/2086 , A61K38/00 , A61K38/08 , A61K38/10 , A61K47/64 , A61K47/6415 , C07K7/06 , C07K7/08 , C07K14/5437 , C07K2319/01 , C07K2319/55
Abstract: A targeting peptide that specifically binds to an IL13 receptor (e.g., wherein said targeting peptide is not an IL13 fragment) is described. The targeting peptide is optionally conjugated to at least one effector molecule. In some embodiments, the peptide specifically binds to the IL13Rα2 protein.
Abstract translation: 描述了特异性结合IL13受体（例如，其中所述靶向肽不是IL13片段）的靶向肽。 靶向肽任选地缀合至至少一个效应分子。 在一些实施方案中，肽特异性结合IL13Rα2蛋白。
-
公开(公告)号：US20160039938A1
公开(公告)日：2016-02-11
申请号：US14776356
申请日：2014-03-14
Applicant: WAKE FOREST UNIVERSITY HEALTH SCIENCES
Inventor： Waldemar Debinski , Denise Mazess Herpai
CPC classification number: C07K16/2866 , A61K39/3955 , A61K47/6813 , A61K47/6829 , A61K47/6849 , A61K47/6851 , A61K47/6911 , A61K49/0004 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C12N9/93 , C12Y603/01004
Abstract: Provided herein is an antibody (e.g., an isolated antibody) that specifically binds an epitope (e.g., linear epitope) within amino acids spanning the extracellular portion of human IL-13RA2. In some embodiments, the amino acids spanning the extracellular portion of human IL-13RA2 have at least 90% identity with the corresponding canine sequence of IL-13RA2. In some embodiments, the antibody specifically binds both human and canine IL-13RA2. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a recombinant antibody. In some embodiments, the antibody is humanized. In some embodiments, the antibody is the monoclonal antibody produced by hybridoma 1E10B9 or a recombinant form thereof.
Abstract translation: 本文提供了特异性结合跨越人IL-13RA2的细胞外部分的氨基酸内的表位（例如，线性表位）的抗体（例如，分离的抗体）。 在一些实施方案中，跨越人IL-13RA2的细胞外部分的氨基酸与IL-13RA2的相应犬序列具有至少90％的同一性。 在一些实施方案中，抗体特异性结合人和犬IL-13RA2。 在一些实施方案中，抗体是单克隆抗体。 在一些实施方案中，抗体是重组抗体。 在一些实施方案中，抗体是人源化的。 在一些实施方案中，抗体是由杂交瘤1E10B9或其重组形式产生的单克隆抗体。
-
-
-
-
-
-
-
-
-
Search Results
36
records
(took 0.024 seconds)
